HeartSciences (NASDAQ:HSCS) Issues Earnings Results

HeartSciences (NASDAQ:HSCS) released its quarterly earnings data on Thursday. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.22), Zacks reports.

HeartSciences Stock Down 2.0%

HSCS stock opened at $2.39 on Friday. The firm has a market capitalization of $7.60 million, a PE ratio of -0.61 and a beta of 1.78. The company has a quick ratio of 1.04, a current ratio of 1.19 and a debt-to-equity ratio of 0.16. HeartSciences has a twelve month low of $1.63 and a twelve month high of $4.30. The stock’s 50 day moving average is $2.27 and its 200-day moving average is $2.50.

Hedge Funds Weigh In On HeartSciences

An institutional investor recently bought a new position in HeartSciences stock. Geode Capital Management LLC bought a new position in HeartSciences Inc. (NASDAQ:HSCS) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned approximately 0.51% of HeartSciences at the end of the most recent reporting period. 17.24% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of HeartSciences in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, HeartSciences currently has a consensus rating of “Hold” and a consensus target price of $8.00.

About HeartSciences

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.